Mylan, Shionogi and CIMA Labs to resolve generic Orapred ODT patent litigation News-Medical.net Mylan Inc. (Nasdaq: MYL) today announced that it has entered into a settlement agreement with Shionogi Inc. and CIMA Labs Inc. that will resolve patent litigation related to Prednisolone Sodium Phosphate Orally Disintegrating Tablets (ODT), 10 mg, 15 ... |
